Opinion
Video
FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer
Author(s):
Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.
EP: 1.Evolving Treatment Paradigms for Early-Stage Breast Cancers
EP: 2.Overview of Genomic Assays for Early-Stage Breast Cancer
EP: 3.MammaPrint: A 70-Gene Signature Test for Patient with Breast Cancer
EP: 4.Clinical Considerations of Genomic Testing in Early-Stage Breast Cancer
Now Viewing
EP: 5.FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer
EP: 6.Exploring Multigene Genomic Assays in High-Risk BC Patients
EP: 7.Real-World Evidence in Genomic Testing from SABCS 2023
EP: 8.Racial Disparities and Genomic Testing for Breast Cancer Patients
EP: 9.Reflecting on Genomic Testing in Practice for Breast Cancer
EP: 10.Ongoing Studies in Genomic Testing for Breast Cancer
Related Videos
Related Content
%201%20(1)-Recovered%20copy.jpg?fit=crop&auto=format)
